Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, has announced an oral presentation on denifanstat’s effect on triglycerides and LDL-cholesterol in advanced fibrosis patients. This presentation will be delivered at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium, held from February 23-26, 2025, in Banff, Canada.
The presentation will feature lipidomic data from a post-hoc analysis of the Phase 2b FASCINATE-2 trial of denifanstat in MASH (Metabolic Associated Steatohepatitis). The title of the presentation is: Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis in a Post-Hoc Analysis of FASCINATE-2 Study. It will be presented by Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational Sciences, during the Symposia Spotlight: Emerging Mechanisms session on Wednesday, February 26, 2025, at 3:00 PM MST, at the Fairmont Banff Springs, Banff, AB, Canada.
Sagimet Biosciences (Nasdaq: SGMT), un'azienda biofarmaceutica in fase clinica, ha annunciato una presentazione orale sull'effetto di denifanstat sui trigliceridi e sul colesterolo LDL nei pazienti con fibrosi avanzata. Questa presentazione si terrà al MASH Pathogenesis and Therapeutic Approaches Keystone Symposium, che si svolgerà dal 23 al 26 febbraio 2025 a Banff, Canada.
La presentazione presenterà dati lipidomici da un'analisi post-hoc del trial di fase 2b FASCINATE-2 di denifanstat in MASH (Steatoepatite Metabolica Associata). Il titolo della presentazione è: Denifanstat, un inibitore della sintesi degli acidi grassi, ha aumentato i trigliceridi polinsaturi circolanti e diminuito il colesterolo LDL nei pazienti MASH con fibrosi avanzata in un'analisi post-hoc dello studio FASCINATE-2. Sarà presentata da Wen-Wei Tsai, Ph.D., Direttore Senior R&D, Scienze Traslazionali, durante la sessione Symposia Spotlight: Emerging Mechanisms mercoledì 26 febbraio 2025, alle 15:00 MST, presso il Fairmont Banff Springs, Banff, AB, Canada.
Sagimet Biosciences (Nasdaq: SGMT), una empresa biofarmacéutica en etapa clínica, ha anunciado una presentación oral sobre el efecto de denifanstat en los triglicéridos y el colesterol LDL en pacientes con fibrosis avanzada. Esta presentación se llevará a cabo en el MASH Pathogenesis and Therapeutic Approaches Keystone Symposium, que se celebrará del 23 al 26 de febrero de 2025 en Banff, Canadá.
La presentación incluirá datos lipidómicos de un análisis post-hoc del ensayo de fase 2b FASCINATE-2 de denifanstat en MASH (Esteatohepatitis Metabólicamente Asociada). El título de la presentación es: Denifanstat, un inhibidor de la síntesis de ácidos grasos, aumentó los triglicéridos polinsaturados circulantes y disminuyó el colesterol LDL en pacientes MASH con fibrosis avanzada en un análisis post-hoc del estudio FASCINATE-2. Será presentada por Wen-Wei Tsai, Ph.D., Director Senior de I+D, Ciencias Traslacionales, durante la sesión Symposia Spotlight: Emerging Mechanisms el miércoles 26 de febrero de 2025, a las 3:00 PM MST, en el Fairmont Banff Springs, Banff, AB, Canadá.
사기멧 바이오사이언스 (Nasdaq: SGMT), 임상 단계의 생명공학 회사가 고급 섬유증 환자에서 데니판스타트의 중성지방 및 LDL-콜레스테롤에 미치는 영향에 대한 구두 발표를 발표했습니다. 이 발표는 2025년 2월 23일부터 26일까지 캐나다 반프에서 열리는 MASH 병인 및 치료 접근법 키스톤 심포지엄에서 진행될 예정입니다.
발표는 MASH(대사 관련 지방간염)에서 데니판스타트의 2b상 FASCINATE-2 시험의 후속 분석에서 얻은 지질 데이터가 포함될 것입니다. 발표 제목은: 지방산 합성 억제제인 데니판스타트가 고급 섬유증을 가진 MASH 환자에서 순환하는 폴리불포화 중성지방을 증가시키고 LDL-콜레스테롤을 감소시킨 후속 분석입니다. 이 발표는 Wen-Wei Tsai, Ph.D., R&D 선임 이사, 전이 과학이 진행하며, 2025년 2월 26일 수요일 오후 3시 MST에 Symposia Spotlight: Emerging Mechanisms 세션에서 발표될 예정입니다. 장소는 캐나다 반프의 Fairmont Banff Springs입니다.
Sagimet Biosciences (Nasdaq: SGMT), une entreprise biopharmaceutique en phase clinique, a annoncé une présentation orale sur l'effet de denifanstat sur les triglycérides et le cholestérol LDL chez les patients atteints de fibrose avancée. Cette présentation sera donnée lors du MASH Pathogenesis and Therapeutic Approaches Keystone Symposium, qui se tiendra du 23 au 26 février 2025 à Banff, Canada.
La présentation comprendra des données lipidomiques issues d'une analyse post-hoc de l'
Sagimet Biosciences (Nasdaq: SGMT), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat eine mündliche Präsentation über die Wirkung von denifanstat auf Triglyceride und LDL-Cholesterin bei Patienten mit fortgeschrittener Fibrose angekündigt. Diese Präsentation wird beim MASH Pathogenesis and Therapeutic Approaches Keystone Symposium stattfinden, das vom 23. bis 26. Februar 2025 in Banff, Kanada, abgehalten wird.
Die Präsentation wird lipidomische Daten aus einer post-hoc Analyse der Phase 2b FASCINATE-2 Studie von denifanstat in MASH (Metabolisch assoziierte Steatohepatitis) enthalten. Der Titel der Präsentation lautet: Denifanstat, ein Inhibitor der Fettsäuresynthese, erhöhte zirkulierende mehrfach ungesättigte Triglyceride und verringerte LDL-Cholesterin bei MASH-Patienten mit fortgeschrittener Fibrose in einer post-hoc Analyse der FASCINATE-2 Studie. Sie wird von Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational Sciences, während der Sitzung Symposia Spotlight: Emerging Mechanisms am Mittwoch, den 26. Februar 2025, um 15:00 Uhr MST im Fairmont Banff Springs, Banff, AB, Kanada, präsentiert.
- Presentation of promising lipidomic data from Phase 2b FASCINATE-2 trial.
- Potential positive impact on triglycerides and LDL-cholesterol in advanced fibrosis patients.
- None.
SAN MATEO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation on denifanstat’s effect on triglycerides and LDL-cholesterol in advanced fibrosis patients will be delivered at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium being held February 23-26, 2025 in Banff, Canada. The presentation will feature lipidomic data from a post-hoc analysis of the Phase 2b FASCINATE-2 trial of denifanstat in MASH.
MASH Pathogenesis and Therapeutic Approaches Keystone Symposium:
| Title: | Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis in a Post-Hoc Analysis of FASCINATE-2 Study |
| Presenter: | Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational Sciences |
| Session: | Symposia Spotlight: Emerging Mechanisms |
| Date/Time: | Wednesday, February 26, 2025 at 3:00 PM MST |
| Location: | Fairmont Banff Springs, Banff, AB, Canada |
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit www.sagimet.com.
About MASH
Metabolic dysfunction associated steatohepatitis (MASH) is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there is only one recently approved treatment in the United States and no currently approved treatments in Europe. In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH. Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver. The goal of the name change was to establish an affirmative, non-stigmatizing name and to improve diagnostic clarity.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related anticipated development milestones, Sagimet’s cash and financial resources and expected cash runway. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions.
The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat or any other drug candidates Sagimet may develop; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines, including its Phase 3 denifanstat program; Sagimet’s relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements; and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
What is the significance of Sagimet Biosciences' presentation at the Keystone Symposium?
When and where will Sagimet Biosciences present its findings on denifanstat?
What are the key findings of the FASCINATE-2 trial presented by Sagimet Biosciences?
Who will present the lipidomic data from the FASCINATE-2 trial at the Keystone Symposium?
What is the focus of Sagimet Biosciences' research presented at the Keystone Symposium?
